ライフサイエンスコーパス: opener

1 erial glibenclamide (blocker) and diazoxide (opener).

2 annel blockers), and diazoxide (KATP channel opener).

3 phosphate-sensitive potassium (KATP) channel opener.

4 orally bioavailable KCNQ2 potassium channel opener.

5 ut diazoxide, a mitochondrial K(ATP) channel opener.

6 was identified as the optimal maxi-K channel opener.

7 tically inactive ARF nucleotide binding-site opener.

8 cked by pinacidil, which is a K(ATP) channel opener.

9 /L; n=6), an ATP-sensitive potassium channel opener.

10 retigabine acts as a KCNQ potassium channel opener.

11 nd their response to a BK channel blocker or opener.

12 an be prevented by retigabine, a Kv7 channel opener.

13 channels and was effective as a K(+) channel opener.

14 xed by pinacidil, a selective K(ATP) channel opener.

15 nels but was not effective as a K(+) channel opener.

16 sitizes the reversible effects by a chemical opener.

17 ituent retain activity as maxi-K ion channel openers.

18 y combining elements from other known maxi-K openers.

19 mutant channels were rescued by KATP channel openers.

20 of sulfonyldihydropyridine-containing K(ATP) openers.

21 4S-stereochemistry act as mitochondrial KATP openers.

22 tricyclic dihydropyridine-containing K(ATP) openers.

23 ow closers was about twice that for the fast openers.

24 eversed by the application of the mitoK(ATP) openers.

25 g, with tolerance improved by K(ATP) channel openers.

26 ine triphosphate-sensitive potassium channel openers.

27 ith sulfonylurea drugs and potassium channel openers.

28 imicked the effects of the potassium channel openers.

29 may mediate the protection from KATP channel openers.

30 PGF2, all of which are putative KATP channel openers.

31 otection for ATP-sensitive K+ channel (KATP) openers.

32 the design of Cx43-interacting gap junction openers.

33 ation with characteristic properties of both openers.

34 serotype 3-derived protein, termed junction opener 1 (JO-1), which binds to the epithelial junction

35 activation with both anti-IgE and the iKCa1 opener 1-EBIO, and was reversed by removing salbutamol o

36 ce of either valinomycin or the K(+) channel opener 1-EBIO.

37 l iodinated 1,4-dihydropyridine KATP channel opener, [125I]A-312110 [(9R)-9-(4-fluoro-3-125iodophenyl

38 on the tricyclic dihydropyridine (DHP) KATP openers 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6

39 ribosylation factor nucleotide-binding site opener, a guanine nucleotide exchange factor of the smal

40 The K(ATP) channel openers, adenosine and levcromakalim, decreased the perf

41 However, diazoxide (a K(+)-ATP channel opener) administered 1 h before FBS addition restored th

42 on, and CAGE (Cut down, Annoyed, Guilty, Eye-opener) alcohol consumption scales.

43 Aprikalim, a selective K(ATP) opener, also induced a potent endothelium-independent an

44 e, TWEAK (Tolerance/Worry About Drinking/Eye-Opener/Amnesia/C[K]ut Down on Drinking), Drug Abuse Seve

45 however, remained sensitive to both channel opener and inhibitor, which indicated that Cys(176) is n

46 ent ATP-sensitive potassium (K(ATP)) channel openers and blockers have implicated opening of mitochon

47 the lack of specificity for several channel openers and blockers have questioned the actual contribu

48 were glyburide-reversible potassium channel openers and hyperpolarized human bladder cells as assess

49 tro effects of established potassium channel openers and inhibitors (tolbutamide and glibenclamide),

50 ed for KATP channel activation by K+ channel openers and nucleotides.

51 owed that l-NNA inhibited dilation by K(ATP) openers and that nitric oxide had no permissive action i

52 ositides), ARNO (Arf nucleotide binding site opener), and Cytohesin-1 bind phosphatidylinositol (PtdI

53 fects of ZD6169, an ATP-sensitive K+-channel opener, and capsaicin, an afferent neurotoxin, on urinar

54 hondrial permeability transition pore (mPTP) opener, and N-methyl-4-isoleucine cyclosporine (NIM811),

55 ischemic preconditioning and K(ATP) channel openers, and it has been suggested that mitoK(ATP) may a

56 ch consists of locally open duplex DNA, PNA "openers," and an oligonucleotide.

57 were negated by the addition of ATR--a mPTP opener--and mimicked by injection of NIM811--a mPTP open

58 Selective potassium channel openers are likely to represent novel therapies for pain

59 ATP-sensitive K+ (KATP) channel openers are vasodilators that activate both plasma membr

60 for both an auxiliary subunit and a chemical opener argue for a mechanistic overlap in causing potent

61 -ribosylation factor nucleotide-binding site opener (ARNO) (evaluation of phosphatidylinositide 3-kin

62 -ribosylation factor nucleotide-binding site opener (ARNO) and ADP-ribosylation factor (ARF)6 have im

63 -ribosylation factor nucleotide binding site opener (ARNO) and general receptor for 3-phosphoinositid

64 ylation factor (ARF) nucleotide-binding site opener (ARNO) in desensitization of the luteinizing horm

65 h the Sec7d from ARF nucleotide-binding site opener (ARNO)/cytohesin-2, a plasma membrane GEF reporte

66 nd its activator ARF nucleotide binding site opener (ARNO; also known as CYTH2).

67 linical basis for the potential use of K(v)7 openers as a targeted anticonvulsant therapy to improve

68 e results and showed that other K(+) channel openers as well as the K(+) ionophore valinomycin also i

69 RNO (ADP-ribosylation factor nucleotide site opener) as well as Arf6 and Arf1 small GTPases are locat

70 Administration of three distinct M-channel openers at 0-6 h after ischemic injury significantly dec

71 Finally, administration of the pore opener atractyloside significantly attenuated the infarc

72 sor effects to BAY K 8644, a calcium-channel opener, attenuated significantly vasodilator responses t

73 Coexposure to the calcium channel opener BayK, or the group I metabotropic glutamate recep

74 (29-32%) by incubation with the Ca2+ channel opener BAYK8644 (1-10 microm).

75 ed, with the aid of two peptide nucleic acid openers, between the two strands of double-stranded DNA

76 The K(ATP) channel opener bimakalim (1 micromol/L) increased postischemic r

77 e C6 position of the cardioprotective K(ATP) opener BMS-180448 (2) is described.

78 itochondrial ATP-sensitive potassium channel opener BMS-191095.

79 creased by simultaneously using another BTB "opener", bradykinin.

80 re pretreated with pinacidil (K+(ATP)channel opener), bradykinin, methacholine, or morphine before re

81 tem that was prevented with a K(ATP) channel opener but not a calcium channel blocker and the other p

82 Diazoxide is a weak cardiac sarcolemmal KATP opener, but it is a potent opener of mitochondrial KATP,

83 radialization of the CCC, conversion to can-opener capsulorhexis, or any combination of the 3 aforem

84 romol/L), an ATP-sensitive potassium channel opener, caused a significant (P<0.001) shortening of the

85 compared to 2 and the first-generation KATP opener cromakalim (1).

86 nd dipeptide derivatives of the KATP channel opener cromakalim and evaluated their IOP lowering capab

87 e K+ ionophore valinomycin or the K+-channel opener cromakalim induced apoptosis.

88 the ATP-sensitive potassium (K(ATP)) channel opener cromakalim.

89 antagonized by the ATP-sensitive K+ channel openers cromakalim, pinacidil, or diazoxide.

90 As a representative of NS1619-like BK openers, Cym04 reversibly left-shifts the half-activatio

91 stages of Ca2+ uptake, the potassium channel openers depolarized the mitochondrial membrane thereby r

92 The mitoKATP channel opener diazoxide (100 micromol/L) partially oxidized the

93 f simulated ischemia, the mitoK(ATP) channel opener diazoxide (100 micromol/L), but not P-1075, blunt

94 The K(+) channels opener diazoxide (200-500 microM) increased channel open

95 Importantly, combination of the KATP channel opener diazoxide and carbamazepine led to enhanced mutan

96 ped membrane potential with the KATP channel-opener diazoxide and KCl to fix Ca(2+) at an elevated le

97 The mitoK(ATP) channel opener diazoxide attenuated the accumulation of [Ca(2+)]

98 The selective K(ATP) channel opener diazoxide hyperpolarized the RMP and attenuated n

99 st time that the mitochondrial K-ATP channel opener diazoxide improves neurological function after sp

100 r exposure to the ATP-dependent K(+) channel opener diazoxide increases mitochondrial resistance to o

101 nRH neurons revealed that the K(ATP) channel opener diazoxide induced an outward current that was ant

102 The KATP channel opener diazoxide is used clinically to treat intractable

103 ATP-sensitive potassium (mitoK(ATP)) channel opener diazoxide markedly decreased the likelihood that

104 with the ATP-sensitive K(+) (K(ATP)) channel opener diazoxide mimicked the effect of reduced glucose,

105 vestigated the effects of mitoK(ATP) channel opener diazoxide on BBB functions during ischemia/reperf

106 The ATP-sensitive K(+) (K(ATP)) channel opener diazoxide or the l-type calcium channel blocker n

107 Application of the K(ATP) channel opener diazoxide or the ob gene product leptin mimicked

108 of either 1) vehicle, 2) the K(ATP) channel opener diazoxide, 3) the K(ATP) channel closer glybencla

109 Neither MgADP, nor the K+ channel opener diazoxide, enhanced Kir6.2/SUR1bDelta33, Kir6.2/S

110 hich stimulate secretion, and the K+ channel opener diazoxide, which inhibits insulin release.

111 s observed, however, with the K(ATP) channel opener diazoxide.

112 effectively mimicked using the mKATP channel opener diazoxide.

113 y mimicked by injection of the mKATP channel opener diazoxide.

114 ) solutions with or without the KATP channel opener diazoxide.

115 mazepine was facilitated by the KATP channel opener diazoxide.

116 ponse to activation by the potassium channel opener diazoxide.

117 57BL/6 mice were treated with K(ATP) channel openers diazoxide (n = 10) and nicorandil (n = 10) for 1

118 P-sensitive potassium channel (KATP channel) openers diazoxide and 7-chloro-3-isopropylamino-4H-1,2,4

119 th glibenclamide and the specific mitoK(ATP) openers diazoxide and BMS-191095.

120 K(ATP) channel openers diazoxide and nicorandil are effective regulator

121 Treatment with the K(+)(ATP) channel openers diazoxide or pinacidil 48 h prior to lethal isch

122 culture and treated with the K(ATP) channel openers diazoxide, nicorandil, and P1075 or the K(ATP) c

123 evaluated the hypothesis that a KATP channel opener (diazoxide) would benefit volume homeostasis by l

124 nclamide, tetraphenylphosphonium cation) and openers (diazoxide, pinacidil, chromakalim, minoxidil, t

125 es; and (4) the SUR activator ("KATP channel opener"), diazoxide, activated the NCCa-ATP channel, whe

126 with the ATP-sensitive K(+) channel agonist (opener) diazoxide, compared with placebo, results in hig

127 The mitoK(ATP) channel opener, diazoxide (50 microM), caused a similar increase

128 ented by the ATP-sensitive potassium channel opener, diazoxide (DZX) via an unknown mechanism.

129 h the mitochondrial ATP-sensitive K+ channel opener, diazoxide, preconditions cells to subsequent inj

130 um cyanide (NaCN), or the mitoK(ATP) channel opener, diazoxide.

131 terminus of Kir6.2 and SUR1, whereas channel openers did not, suggesting the inhibitors enhance inter

132 d GABA, whereas cromakalim, a SUR2-selective opener, did not.

133 Application of a K(ATP) channel opener drug improved survival in the endotoxic WT but ha

134 sensitivity to sulphonylurea and K+ channel opener drugs, and the potentiatory action of MgADP.

135 y relative to the potent vasodilating K(ATP) openers (e.g., cromakalim).

136 ugh ATP-sensitive potassium (K(ATP)) channel openers, e.g., minoxidil and diazoxide, can induce hair

137 ic vacuole, whereas NS1619, a BK(Ca) channel opener, enhanced both.

138 Kv7 (KCNQ) potassium channel openers (enhancers) decrease neuropathic pain in experim

139 udy assessed the effects of the KCNQ channel opener ezogabine (also known as retigabine) on reward ci

140 stration of SB216763 and atractyloside (MPTP opener) failed to abrogate a local cytoprotective Gsk3be

141 Application of the selective KCNQ opener flupirtine raised A-axon firing threshold while p

142 ective and vasorelaxant properties of K(ATP) openers follow distinct structure-activity relationships

143 o hyperpolarized with diazoxide, a selective opener for K(ATP) channels containing sulfonylurea recep

144 bunits, but not with cromakalim, a selective opener for SUR2-based channels, indicating that SUR1-bas

145 -fluoro-phenyl)-acr ylamide ((S)-2) as KCNQ2 openers for further electrophysiological evaluations.

146 Chemical openers for KCNQ potassium channels are useful probes bo

147 s the ability of pyrimidine PNAs to serve as openers for specific DNA sites by invading the DNA duple

148 force in response to KCl, the L-type channel opener FPL64176, or the SMC agonists 5-HT and ET-1, and

149 la mide (2), as an orally bioavailable KCNQ2 opener free of CYP3A4 MDI.

150 ATP-sensitive potassium (KATP) channel openers have emerged as potential therapeutics for the t

151 ocampus, with channel blockers enhancing and openers impairing spontaneous alternation performance, t

152 annel inhibitor and a surface K(ATP) channel opener in native cardiac cells.

153 ssion, we report that KCNQ-type K(+) channel openers, including FDA-approved drug retigabine (ezogabi

154 ux mediated by 1-EBIO, we found that this SK opener increased apoptosis of PLB-985 cells.

155 K(ATP) channel openers increased outflow facility in human anterior seg

156 tion of arachidonic acid (10 mum), a channel opener, increased the open probability of methionine-inh

157 tening by an ATP-sensitive potassium channel opener increases ventricular vulnerability to reentry an

158 potentiation by multiple synthetic chemical openers indicates that KCNQ channels are accessible to v

159 Opener-induced channel activation was also inhibited by

160 s sought to determine whether K(ATP) channel openers influence outflow facility in human anterior seg

161 icrom), a permeability transition pore (PTP) opener, inhibited transient K(Ca) currents similarly to

162 tivity of the identified abdominal ascending opener interneuron, a homologous key component of the si

163 ltage-gated potassium channels by a chemical opener is uncommon.

164 efore, the molecular specificity of chemical openers is an important subject of investigation.

165 osphate-sensitive potassium (K(ATP)) channel openers is described.

166 ischemic preconditioning and K(ATP) channel openers is known to involve the mitochondrial ATP-sensit

167 Binding of channel openers is reported to require ATP hydrolysis, but diazo

168 ARNO (ARF nucleotide-binding site opener) is a member of a growing family of ARF-GEFs that

169 he synthesis of ABT-598, a potassium channel opener, is demonstrated.

170 ial of the SUR-1-selective potassium channel opener (KCO), NN414, to amplify counterregulatory respon

171 r the cardioprotective effects of K+ channel openers (KCO) and for the blocking of cardioprotection b

172 lic sensors and targets of potassium channel openers (KCO; e.g., diazoxide and pinacidil).

173 nsive ATP-sensitive potassium (KATP) channel openers (KCOs) activate plasma membrane KATP channels an

174 10 by structurally diverse potassium channel openers (KCOs) indicated a similar rank order of potency

175 vel series of benzylamine, potassium channel openers (KCOs) is presented as part of our program towar

176 muscle cell K(ATP) channels to K(+) channel openers (KCOs) is the basis for the selective prevention

177 g novel, bladder-selective potassium channel openers (KCOs) targeted for urge urinary incontinence (U

178 channels) are the target for K(ATP)-channel openers (KCOs), such as pinacidil and P1075.

179 otides, sulfonylureas, and potassium channel openers, KCOs.

180 opening of mitoKATP similar to KATP channel openers like diazoxide and cromakalim in heart, liver, a

181 Notably, the Slack opener loxapine ameliorated persisting neuropathic pain

182 lume hyper-absorption was reversed by the BK opener mallotoxin and the clinically useful TGF-beta sig

183 Our data suggest that K(+) channel openers may be capable of abbreviating the long QT inter

184 botanical KCNQ5-selective potassium channel openers may enable future targeted therapies for disease

185 oncept that bladder-selective K(ATP) channel openers may have utility in the treatment of overactive

186 KCNQ channel openers merit further study as potential treatments for

187 K(ATP) channel openers (minoxidil, cromakalim, and pinacidil) increased

188 With the aid of PNA "openers", molecular beacons were employed for the detect

189 Long-term facilitation at the crayfish opener muscle is elicited by prolonged high frequency st

190 r and the quantal parameters: n and p in the opener muscle of the walking leg in crayfish.

191 ) on the inhibitory junction of the crayfish opener muscle.

192 boxy terminus overlaps with that of the KCNQ opener N-ethylmaleimide (NEM).

193 ctive therapy with adenosine, K(ATP) channel openers, Na(+)/H(+) exchange inhibitors, and hypothermia

194 lamide), plus a novel, selective Kir6.2/SUR1 opener, NNC 55-0118, were assessed on deer hair follicle

195 at was absent in ECs, and the BK(Ca) channel opener NS 1619 only enhanced K(+) current in the SMCs.

196 deannulation of known benzimidazolone maxi-K opener NS-004 (2) thereby providing an effective templat

197 n contrast, the alpha-subunit-selective BKCa opener, NS-1619 (20 microM), exerted a similar effect in

198 Addition of the BK channel opener NS11021 directly activated channels in control ep

199 ibited the oscillations, whereas the channel opener NS11021 increased the rate of these oscillations.

200 el-mediated unitary currents, the BK channel opener NS1619 attenuated the effects of METH on action p

201 e activation of BK channels with the channel opener NS1619 reversibly attenuated the mean amplitude o

202 ium channels, termed CAL, and a photochromic opener of G protein-coupled inwardly rectifying potassiu

203 shed by treatment with pinacidil, a specific opener of KATP channels.

204 Diazoxide is the prototypical opener of mitochondrial ATP-sensitive potassium channels

205 protection afforded by diazoxide (Diaz), an opener of mitochondrial K(ATP) channels.

206 sarcolemmal KATP opener, but it is a potent opener of mitochondrial KATP, making it a useful tool fo

207 2',3'-cAMP to 2'-AMP; 2',3'-cAMP is a potent opener of mitochondrial permeability transition pores (m

208 tochondrial K+ uptake of the myocyte, and an opener of mitoKCa protected hearts against infarction.

209 Compound 8a (BMS-191011), an opener of the cloned large-conductance, Ca2+-activated p

210 Diazoxide, a selective opener of the mitochondrial ATP-sensitive potassium chan

211 s were pretreated with diazoxide, a specific opener of the mitoK(ATP) channel (7 mg/kg, IV), 12, 24,

212 l, we tested whether the potent and specific opener of the MitoKATP channel diazoxide attenuates the

213 Openers of K(v)7.4 channels have been suggested to impro

214 is study tests the hypothesis that selective openers of KCNQ channels may be effective for treatment

215 To protect these neurons, we have developed openers of large-conductance, Ca++-activated (maxi-K or

216 otent, effective and uniquely Ca++-sensitive openers of maxi-K channels.

217 Pharmacological openers of mitochondrial ATP-dependent K+ (mitoKATP) cha

218 luated by electrophysiological techniques as openers of the cloned mammalian large-conductance, Ca(2+

219 e derivatives were prepared and evaluated as openers of the cloned maxi-K channel hSlo expressed in X

220 Since both lipids are openers of TREK-1, it has been suggested that this K(2P)

221 e C-2, and C-6 positions were synthesized as openers of vascular KATP channels.

222 b, but not rofecoxib, is shown to act as an "opener" of voltage-gated KCNQ5 K(+) channels and a block

223 in vitro, however, the effects of mitoK(ATP) openers on cerebral endothelial cells and on BBB functio

224 The effect of these maxi-K openers on corporal smooth muscle was studied in vitro u

225 nd D1469N mutations attenuated the effect of openers on KATP channel activity.

226 ere examined the action of potassium channel openers on mitochondrial Ca2+ homeostasis, as these card

227 stigated the protective effects of M-channel openers on stroke-induced brain injury in mouse photothr

228 dministration of ZD6169, a potassium channel opener, on neurally mediated plasma extravasation in the

229 es the effects of nicorandil, a K(+) channel opener, on transmural dispersion of repolarization (TDR)

230 dentify an essential single copy gene called OPENER (OPNR) in Arabidopsis.

231 cellular application of selective SK-channel openers or a genetic reintroduction of an N-terminal FMR

232 BK channel openers or BK channel gene transfer could be an alternat

233 ding motifs classifies them as predominantly openers or closers of local chromatin accessibility, pin

234 nge factor ARNO (ARF nucleotide binding site opener) or inactive ARF6 enhanced dendritic branching, w

235 inacidil (2 to 5 micromol/L), a K(+) channel opener, or the combination of a Na(+) channel blocker (f

236 in control of neuronal discharge, M channel openers, or blockers, reduced or augmented the evoked re

237 ed for drug development aimed at ion channel opener- or inhibitor-function.

238 annel blocker HMR1098 and the K(ATP) channel opener P-1075 on surfaceK(ATP) and mitoK(ATP) channels i

239 kedly activated by cyanide (CN) or the known opener P1075 with a current density that was ~8-fold sma

240 retigabine, a recently marketed KV 7 channel opener, partially reversed these effects for the majorit

241 ine triphosphate-sensitive potassium channel opener (PCO)-induced hyperpolarized arrest with pinacidi

242 tive potassium channels by potassium channel openers (PCO) within the myocyte appears to confer a pro

243 has demonstrated that the potassium channel openers (PCOs) aprikalim and pinacidil are effective car

244 Pretreatment with potassium channel openers (PCOs) has been shown to provide protective effe

245 In these cells, the potassium channel opener pinacidil (10 micromol/L) did not prevent Ca2+ lo

246 e study was repeated with the K(ATP) channel opener pinacidil (n=6) and the calcium channel blocker f

247 n of coronary arterioles to the KATP-channel opener pinacidil and to the endothelium-independent vaso

248 arcKATP channels preactivated by the channel opener pinacidil in rabbit ventricular myocytes, through

249 given only at reperfusion, the K(+) channel opener pinacidil or the antioxidants 2-mercaptopropionyl

250 t vasorelaxation induced by the KATP channel opener pinacidil.

251 ted KATP current activated by the K+ channel opener pinacidil.

252 nel blocker nisoldipine and the K(+) channel opener pinacidil.

253 we found that the effects of K(ATP) channel openers, PKG, or valinomycin were mediated by a PKCepsil

254 K(ATP) channel openers prevent detrimental myocyte swelling and reduce

255 Thus, potassium channel openers prevent mitochondrial Ca2+ overload by reducing

256 urea receptor 1 (SUR1)selective KATP-channel opener, prevented DA modulation by H2O2, glutamate, and

257 ribosylation factor nucelotide-binding site opener promotes the release of docked beta-arrestin from

258 metabolic inhibition and mitoK(ATP) channel openers protect both the whole organ and isolated cells

259 At higher concentrations, openers reduced ATPase activity, possibly through stabil

260 micromol/L diazoxide, a mito K(ATP) channel opener, reduced infarction to 3+/-1% and 8+/-1%, respect

261 These data indicate that KATP channel openers regulate arterial diameter via SUR-dependent and

262 In contrast, the Kv7 channel opener retigabine increased I(M) amplitude and I(hold).

263 NQ channel blocker XE991 or the KCNQ channel opener retigabine reverses the effects on consolidation

264 resence or absence of the specific M-channel opener retigabine, or agonists of bradykinin B2 or purin

265 s prevented by incubation with the M-channel opener retigabine.

266 ically or by local infusion of the M-channel opener, retigabine.

267 ysfunction in Kcna1-null mice, and that KCNQ openers reveal a transcompartmental synergy between Kv1

268 , and increased by the L-type Ca(2+) channel opener, S(-)-Bay K 8644.

269 results show that diazoxide, a KATP channel opener, selectively activates mitochondrial KATP channel

270 hecal injection of pinacidil, a KATP channel opener, significantly increased the tactile withdrawal t

271 In the cell, channel openers stabilized posthydrolytic states promoting K(ATP

272 ume with a range of ATP-sensitive K+ channel openers such as diazoxide.

273 ufficient to cause cerebellar ataxia, and SK openers such as the neuroprotective agent riluzole may r

274 al opener, such as GTP, or a pharmacological opener, such as diazoxide.

275 as induced by Mg2+, ATP, and a physiological opener, such as GTP, or a pharmacological opener, such a

276 model-based gating analysis revealed that BK openers, such as Cym04 and NS1619 but not mallotoxin, ac

277 Although KCNQ channel openers, such as retigabine, have emerged as anti-epilep

278 ATP-sensitive potassium channel (K(ATP)) openers target key cellular events, many of which have b

279 By contrast, diazoxide, a potassium channel opener that also binds SUR1, had no effect on surface ex

280 Retigabine, an M-channel opener that does not open receptor-suppressed M-channels

281 caffeic acid derivatives as novel K+ channel openers that activate TREK-1 background K+ channels.

282 t manner, of both novel channel blockers and openers that interact with cardiac/smooth muscle-type KA

283 When activated by K(ATP) channel openers, these channels increase outflow facility throug

284 CF therapies may require the use of channel openers to activate mutant CFTR channels at the cell sur

285 The most promising maxi-K openers to emerge from this study were (+/-)-3-(5-chloro

286 enclamide (KATP blocker) and pinacidil (KATP opener) treatment not only affect macrophage polarizatio

287 However, the Na+ channel opener veratridine (10 and 50 microM) significantly incr

288 loading irrespective of whether the channel opener was applied throughout the duration of hypoxia-re

289 From this study, a potent maxi-K opener was identified as an effective relaxant of rabbit

290 Dilation to NS1619 (KCa channel opener) was reduced in endothelial denuded arterioles tr

291 by pinacidil (100 microM), a K(ATP) channel opener, was significantly higher in E2-treated compared

292 se to levcromakalim (LEVC), a K(ATP) channel opener, was significantly shifted to the left in the inf

293 enosine receptor agonists and a KATP channel opener were used to achieve early preconditioning, and M

294 ted by using adenosine and potassium-channel openers (which are thought to induce hyperpolarized arre

295 ylation factor (ARF) nucleotide binding site opener, which acts as a guanine nucleotide exchange fact

296 ne (ZnPy) is a newly identified KCNQ channel opener, which potently activates KCNQ2, KCNQ4, and KCNQ5

297 KATP channel openers, which bind to SUR, promoted ATPase activity in

298 rototype of a novel series of K(ATP) channel openers with unique selectivity for bladder smooth muscl

299 cacy of flupirtine, a selective KCNQ channel opener, with phenobarbital and diazepam, two drugs in cu

300 , inhibited the effects of potassium channel openers, without preventing the action of valinomycin.